Insider Trading Alert - PACW, QCOR, ALB, FAST And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 31, 2014, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $72.21 to $38,045,742.50.

Highlighted Stocks Traded by Insiders:

PacWest Bancorp (PACW) - FREE Research Report

Dunn Stephen M who is Director at PacWest Bancorp sold 18,000 shares at $41.50 on Jan. 31, 2014. Following this transaction, the Director owned 2,000 shares meaning that the stake was reduced by 90% with the 18,000-share transaction.

The shares most recently traded at $39.75, down $1.75, or 4.4% since the insider transaction. Historical insider transactions for PacWest Bancorp go as follows:

  • 4-Week # shares bought: 8,000
  • 4-Week # shares sold: 13,433
  • 12-Week # shares bought: 8,000
  • 12-Week # shares sold: 53,059
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 53,059

The average volume for PacWest Bancorp has been 495,200 shares per day over the past 30 days. PacWest Bancorp has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are down 3.22% year-to-date as of the close of trading on Friday.

PacWest Bancorp operates as the bank holding company for Pacific Western Bank that provides commercial banking products and services to small to medium sized businesses, and the owners and employees of those businesses primarily in Southern California. The stock currently has a dividend yield of 2.45%. The company has a P/E ratio of 26.0. Currently there are 6 analysts that rate PacWest Bancorp a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PACW - FREE

TheStreet Quant Ratings rates PacWest Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full PacWest Bancorp Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Questcor Pharmaceuticals (QCOR) - FREE Research Report

Broadwood Partners Lp who is Director at Questcor Pharmaceuticals sold 50,000 shares at $66.55 on Jan. 31, 2014. Following this transaction, the Director owned 5.5 million shares meaning that the stake was reduced by 0.91% with the 50,000-share transaction.

The shares most recently traded at $67.08, up $0.53, or 0.78% since the insider transaction. Historical insider transactions for Questcor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 520,000
  • 24-Week # shares bought: 3,250
  • 24-Week # shares sold: 520,000

The average volume for Questcor Pharmaceuticals has been 2.0 million shares per day over the past 30 days. Questcor Pharmaceuticals has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are up 23.07% year-to-date as of the close of trading on Friday.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The stock currently has a dividend yield of 1.79%. The company has a P/E ratio of 15.4. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on QCOR - FREE

TheStreet Quant Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Questcor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Albemarle (ALB) - FREE Research Report

Sherman John Jr who is Director at Albemarle sold 1,000 shares at $65.27 on Jan. 31, 2014. Following this transaction, the Director owned 1,600 shares meaning that the stake was reduced by 38.46% with the 1,000-share transaction.

Zumstein Ronald C who is Sr VP, Mfg & Supply Chain at Albemarle sold 5,291 shares at $64.67 on Jan. 31, 2014. Following this transaction, the Sr VP, Mfg & Supply Chain owned 3,302 shares meaning that the stake was reduced by 61.57% with the 5,291-share transaction.

Wilson D Michael who is Sr VP,Pres, Catalyst Solutions at Albemarle bought 5,000 shares at $64.84 on Jan. 31, 2014. Following this transaction, the Sr VP,Pres, Catalyst Solutions owned 5,000 shares meaning that the stake was reduced by 100% with the 5,000-share transaction.

Juneau Matthew who is Sr VP, Pres, Performance Chem at Albemarle sold 5,000 shares at $64.84 on Jan. 31, 2014. Following this transaction, the Sr VP, Pres, Performance Chem owned 6,519 shares meaning that the stake was reduced by 43.41% with the 5,000-share transaction.

The shares most recently traded at $62.65, down $2.19, or 3.5% since the insider transaction. Historical insider transactions for Albemarle go as follows:

  • 4-Week # shares sold: 5,290
  • 12-Week # shares sold: 5,290
  • 24-Week # shares sold: 5,290

The average volume for Albemarle has been 571,700 shares per day over the past 30 days. Albemarle has a market cap of $5.3 billion and is part of the basic materials sector and chemicals industry. Shares are up 1.25% year-to-date as of the close of trading on Friday.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals. The stock currently has a dividend yield of 1.49%. The company has a P/E ratio of 15.9. Currently there are 4 analysts that rate Albemarle a buy, no analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALB - FREE

TheStreet Quant Ratings rates Albemarle as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Albemarle Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Fastenal Company (FAST) - FREE Research Report

Ancius Michael J who is Director at Fastenal Company bought 120 shares at $44.30 on Jan. 31, 2014. Following this transaction, the Director owned 430 shares meaning that the stake was reduced by 38.71% with the 120-share transaction.

Heise Rita J. who is Director at Fastenal Company bought 1,000 shares at $44.27 on Jan. 31, 2014. Following this transaction, the Director owned 2,000 shares meaning that the stake was reduced by 100% with the 1,000-share transaction.

The shares most recently traded at $42.90, down $1.37, or 3.19% since the insider transaction. Historical insider transactions for Fastenal Company go as follows:

  • 4-Week # shares bought: 8,665
  • 4-Week # shares sold: 200,000
  • 12-Week # shares bought: 8,665
  • 12-Week # shares sold: 200,000
  • 24-Week # shares bought: 14,600
  • 24-Week # shares sold: 300,000

The average volume for Fastenal Company has been 2.3 million shares per day over the past 30 days. Fastenal Company has a market cap of $13.1 billion and is part of the industrial goods sector and materials & construction industry. Shares are down 6.84% year-to-date as of the close of trading on Friday.

Fastenal Company, together with its subsidiaries, operates as a wholesaler and retailer of industrial and construction supplies in the United States, Canada, and internationally. The company offers fasteners and other industrial and construction supplies under the Fastenal name. The stock currently has a dividend yield of 2.26%. The company has a P/E ratio of 29.3. Currently there are 3 analysts that rate Fastenal Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FAST - FREE

TheStreet Quant Ratings rates Fastenal Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Fastenal Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Hsiao Jane Ph D who is Vice Chairman & CTO at Opko Health bought 10,000 shares at $8.14 on Jan. 31, 2014. Following this transaction, the Vice Chairman & CTO owned 21.3 million shares meaning that the stake was reduced by 0.05% with the 10,000-share transaction.

The shares most recently traded at $7.73, down $0.41, or 5.28% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.4 million shares per day over the past 30 days. Opko Health has a market cap of $3.3 billion and is part of the health care sector and health services industry. Shares are down 6.04% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%